Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FTC Asks Roche for More Information on Illumina Offer

By Pharmaceutical Processing | March 14, 2012

The Federal Trade Commission has asked Swiss pharmaceutical company Roche Holding AG for more information related to its $5.7 billion hostile takeover offer for diagnostics company Illumina Inc.

Illumina’s board unanimously turned down Roche’s offer last month, saying it was “grossly inadequate” and that shareholders should not tender their stock to Roche. The board also said that Roche was not properly valuing the growth potential of Illumina’s business, its products in development and its track record.

Roche went public with its $44.50 per share offer in January after Illumina refused to enter negotiations. Illumina then adopted a “poison pill” measure intended to ward off unwanted attempts to acquire the company.

Illumina shares are trading well above the offered price, closing at $50.34 per share on Tuesday.

Illumina, which is based in San Diego, makes systems that analyze an individual’s DNA, and it is the biggest gene-sequencing company. It’s expected that future breakthroughs will use that information to tailor treatments in ways that are especially effective for people with certain genes.

Roche said Tuesday that the FTC is looking for more information on its microarray business. The request extends the waiting period on the proposed deal by 10 days after Roche gives the FTC the information it asked for, unless voluntarily extended by Roche or ended sooner by the FTC.

Roche said that it will continue to cooperate with the FTC.

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE